Chloe Dimeglio

Dr. Chloe Dimeglio

Virology Laboratory, Toulouse University Hospital, 330 avenue de Grande Bretagne 31059, 31300 Toulouse, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2021 in Journal of Infection
Verified
Journal Article
Closed access
CDChloe Dimeglio
Chloe Dimeglio
FHFabrice Herin
Fabrice Herin
GMGuillaume Martin-Blondel
Guillaume Martin-Blondel
MMMarcel Miedougé
Marcel Miedougé
JIJacques Izopet
Jacques Izopet

1 September 2020 in Journal of Clinical Virology
Verified
Journal Article
Closed access
MMMarion Migueres
Marion Migueres
CMCatherine Mengelle
Catherine Mengelle
CDChloe Dimeglio
Chloe Dimeglio
ADAlain Didier
Alain Didier
MAMuriel Alvarez
Muriel Alvarez
JIJacques Izopet
Jacques Izopet

17 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
CDChloe Dimeglio
Chloe Dimeglio
MMMarion Migueres
Marion Migueres
NBNaémie Bouzid
Naémie Bouzid
SCSabine CHAPUY-REGAUD
Sabine CHAPUY-REGAUD
CGCaroline Gernigon
Caroline Gernigon
JIJacques Izopet
Jacques Izopet
The emergence of the SARS-CoV-2 variants of concern has greatly influenced the immune correlates of protection, and there are little data about the antibody threshold concentrations to protect against infection with SARS-CoV-2 Omicron BA.1 or BA.2. We analyzed the antibody responses of 259 vaccinated healthcare workers, some of whom had been previously infected by SARS-CoV-2. The median follow-up was 179 days (IQR: 171–182) after blood collection. We detected 88 SARS-CoV-2 Omicron infections during the follow-up period, 55 (62.5%) with SARS-CoV-2 BA.1, and 33 (37.5%) with SARS-CoV-2 BA.2. A neutralizing antibody titer below 8 provided no protection against a BA.1 infection, a titer of 16 or 32 gave 73.2% protection, and a titer of 64 or 128 provided 78.4% protection. Conversely, the BA.2 infection rate did not vary as a function of anti-BA.2 neutralizing antibody titers. Binding antibody concentrations below 6000 BAU/mL provided no protection against Omicron BA.1 infection, 6000–20,000 BAU/mL provided 55.6% protection, and 20,000 or more provided 87.7% protection. There was no difference in BA.2 infection depending on the binding antibody concentration. Further studies are needed to investigate the relationship between antibody concentrations and infection with the Omicron BA.4/5 variants that are becoming predominant worldwide.

3 February 2022 in Journal of Infection
Verified
Journal Article
Closed access
CDChloe Dimeglio
Chloe Dimeglio
MMMarion Migueres
Marion Migueres
JMJean-Michel Mansuy
Jean-Michel Mansuy
SSSylvie Saivin
Sylvie Saivin
MMMarcel Miedougé
Marcel Miedougé
JIJacques Izopet
Jacques Izopet

7 February 2022 in Journal of Infection
Verified
Journal Article
Closed access
MMMarion Migueres
Marion Migueres
CDChloe Dimeglio
Chloe Dimeglio
PTPauline Trémeaux
Pauline Trémeaux
FAFlorence Abravanel
Florence Abravanel
SRStéphanie Raymond
Stéphanie Raymond
JIJacques Izopet
Jacques Izopet

2 September 2021 in Journal of Clinical Virology
Verified
Journal Article
Closed access
MMMarion Migueres
Marion Migueres
Sébastien LhommeSébastien Lhomme
Sébastien Lhomme
PTP. Trémeaux
P. Trémeaux
CDChloe Dimeglio
Chloe Dimeglio
NRNoemie Ranger
Noemie Ranger
JIJ. Izopet
J. Izopet